Department of Pharmacology, Université de Montréal, Montréal, QC, Canada.
Research Center CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada.
Sci Rep. 2016 Nov 22;6:37391. doi: 10.1038/srep37391.
Pathological choroidal neovascularization (CNV) is the common cause of vision loss in patients with age-related macular degeneration (AMD). Macrophages possess potential angiogenic function in CNV. We have demonstrated that human T lymphocyte-derived microparticles (LMPs) exert a potent antiangiogenic effect in several pathological neovascularization models. In this study, we investigated the alteration of proangiogenic properties of macrophages by LMPs treatment in vitro and in vivo models. LMPs regulated the expression of several angiogenesis-related factors in macrophages and consequently stimulated their antiangiogenic effects evidenced by the suppression of the proliferation of human retinal endothelial cells in co-culture experiments. The involvement of CD36 receptor in LMPs uptake by macrophages was demonstrated by in vitro assays and by immunostaining of choroidal flat mounts. In addition, ex vivo experiments showed that CD36 mediates the antiangiogenic effect of LMPs in murine and human choroidal explants. Furthermore, intravitreal injection of LMPs in the mouse model of laser-induced CNV significantly suppressed CNV in CD36 dependent manner. The results of this study suggested an ability of LMPs to alter the gene expression pattern of angiogenesis-related factors in macrophages, which provide important information for a new therapeutic approach for efficiently interfering with both vascular and extravascular components of CNV.
病理性脉络膜新生血管(CNV)是年龄相关性黄斑变性(AMD)患者视力丧失的常见原因。巨噬细胞在 CNV 中具有潜在的血管生成功能。我们已经证明,人类 T 淋巴细胞衍生的微颗粒(LMPs)在几种病理性新生血管模型中具有强大的抗血管生成作用。在这项研究中,我们研究了 LMPs 处理在体外和体内模型中对巨噬细胞促血管生成特性的改变。LMPs 调节了巨噬细胞中几种与血管生成相关的因子的表达,从而刺激了它们的抗血管生成作用,这表现在共培养实验中抑制了人视网膜内皮细胞的增殖。通过体外测定和脉络膜扁平标本的免疫染色,证明了 CD36 受体参与了巨噬细胞对 LMPs 的摄取。此外,离体实验表明,CD36 介导了 LMPs 在鼠和人脉络膜外植体中的抗血管生成作用。此外,在激光诱导的 CNV 小鼠模型中玻璃体内注射 LMPs 可显著抑制 CNV,这种抑制作用依赖于 CD36。这项研究的结果表明,LMPs 能够改变巨噬细胞中与血管生成相关的因子的基因表达模式,这为一种新的治疗方法提供了重要信息,可有效干扰 CNV 的血管和血管外成分。